Patterns of Energy Drink Use, Risk Perception, and Regulatory Attitudes in the Adult Polish Population: Results of a Cross-Sectional Survey
Abstract
Background: From 1 January 2024, Poland legally banned the sale of energy drinks (EDs) containing caffeine and taurine to minors under 18. EDs are rich in stimulants, making them particularly popular among adolescents and young adults seeking energy boosts. Their consumption is associated with adverse health effects and engagement in risky behaviors. This descriptive snapshot study explores energy drink consumption, motivations, and risk perception among Polish adults. Methods: A cross-sectional, nationwide survey (N = 1121) was conducted over a three-day period using the computer-assisted web interviewing (CAWI) method. The sample was representative of the adult Polish population in terms of gender, age, and geographical location. Data collection occurred 14 months after the implementation of legal restrictions on ED sales to minors. Results: Among 1121 adults (54.3% female), 15.1% reported weekly ED consumption, 9.7% monthly, 13.3% less than monthly, and 62.0% never. Younger age (p < 0.05), male gender (aOR = 1.63 [1.25–2.13]; p < 0.001), and active occupational status (aOR = 1.63 [1.19–2.24]; p = 0.002) were significantly associated with ED use. Overall, 83.0% of respondents perceived EDs as harmful, and 87.2% supported the sales ban to minors, although only 45.6% considered the ban effective. Additionally, 31.8% had observed minors consuming EDs in the past 30 days. Sociodemographic characteristics were associated with risk perception and support for regulation: women…
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.